Impact of Tobacco Cessation on the Development of Bladder Cancer

Video

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.

Vikram Narayan, MD, spoke with CancerNetwork® at the Society of Urologic Oncology 21st Annual Meeting regarding tobacco cessation and how patients are often unaware of its role in helping to prevent bladder cancer recurrence.

Transcription:

I think this is a very promising time. The only other thing that I always mention to all of my patients that I think is really important is tobacco cessation and the fact that many people don’t realize that smoking, including secondhand smoke, is often the single leading cause of bladder cancer. I think efforts to try and quit smoking and get support to do so are going to be really important. It’s great that we have a lot of emerging treatment options but working on a plan and getting support to quit smoking is among the most important things that an individual can do to prevent bladder cancer recurrence. There are a lot of options available, both through a patient’s primary care physician as well as their urologist, if that’s something they are interested in pursuing.

Recent Videos
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content